Why the study?
Lysyl oxidase and LOX-like proteins are copper-dependent metalloenzymes with roles in metastasis, but the mechanism delivering copper to them is poorly understood.
Does silencing of ATP7A reduce LOX activity and metastasis in breast and lung cancer models?
Does silencing of ATP7A reduce LOX activity and metastasis in breast and lung cancer models?
ATP7A is necessary for the activity of LOX and LOXL enzymes, identifying it as a potential therapeutic target for blocking LOX- and LOXL-dependent malignancies and metastasis.
Answers are grounded in this paper and cite their sources.
ATP7A inhibition may block metastasis in models; leaves open clinical translation and requires human trials.
Lysyl oxidase (LOX) and LOX-like (LOXL) proteins are copper-dependent metalloenzymes with well-documented roles in tumor metastasis and fibrotic diseases. The mechanism by which copper is delivered to these enzymes is poorly understood. In this study, we demonstrate that the copper transporter ATP7A is necessary for the activity of LOX and LOXL enzymes. Silencing of ATP7A inhibited LOX activity in the 4T1 mammary carcinoma cell line, resulting in a loss of LOX-dependent mechanisms of metastasis, including the phosphorylation of focal adhesion kinase and myeloid cell recruitment to the lungs, in an orthotopic mouse model of breast cancer. ATP7A silencing was also found to attenuate LOX activity and metastasis of Lewis lung carcinoma cells in mice. Meta-analysis of breast cancer patients found that high ATP7A expression was significantly correlated with reduced survival. Taken together, these results identify ATP7A as a therapeutic target for blocking LOX- and LOXL-dependent malignancies.
No takes yet. Share an insight, caveat, or question.
Shanbhag et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: